Sibionics

Sibionics (硅基仿生) is an AI medical device company focused on serving diabetes patients, operating as a portfolio company of Source Code Capital's "MaHui" member network . The company completed a C-series financing totaling over 800 million yuan across three rounds, with Source Code Capital serving as the lead investor in the C round . Source Code Capital partner Yungang Huang was recognized as Best Digital Healthcare Investor in part for his investments in Sibionics, alongside Bota Biosciences, Keya Medical, and others , and Huang later made the Forbes China Midas List partly on the strength of his bet on the then-unicorn Sibionics . elsewhere's corpus does not contain further detail on Sibionics's specific products, founding date, or clinical pipeline.